The primary objective is to determine the safety and tolerability of INCB000928 as
monotherapy or combined with ruxolitinib. Secondary objectives are to determine the
efficacy of INCB000928 as monotherapy or combined with ruxolitinib (anemia response,
duration of anemia response, mean change from baseline in hemoglobin, and RBC transfusion
rate through weeks 24 and 48); evaluate INCB000928 pharmacokinetics; and evaluate effects
of INCB000928 as monotherapy or combined with ruxolitinib on hepcidin levels and other
measures of iron homeostasis and erythropoiesis.